A new class of engineered proteins may counter infection caused by Staphylococcus aureus - a bacterial species considered one of the largest global health threats, a new study suggests. Published ...
Study shows efficacy and safety of oral antibiotic therapy in the form of pills for Staphylococcus aureus bloodstream infections. Currently, infusions are the standard treatment. An international ...
Developers working on methicillin-resistant staphylococcus aureus (MRSA) treatments market are expected to invest resources into research and development activities, for the generation of new product ...
Staphylococcus aureus bacteremia and endocarditis are serious infections that demand prompt clinical attention to ensure good outcomes. Of foremost importance is identifying and managing the source of ...
Linezolid Nosocomial pneumonia, cSSSI Oral and intravenous form available, bacteriostatic, not approved for catheter-related bloodstream infections, side effects include myelosuppression, ...
NEW YORK--(BUSINESS WIRE)-- Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, ...
Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, although the Methicillin-resistant (MRSA) drugmarket is currently ...
Methicillin-resistant Staphylococcus aureus (MRSA) is a serious bacterial infection that is resistant to most antibiotic treatments. Healing is possible but severe infections may become chronic or ...
A National Institutes of Health (NIH)-supported clinical trial has found that the outcome of treating complicated Staphylococcus aureus bloodstream infections with two intravenous (IV) doses of the ...
BROOKLYN, N.Y., Jan. 16, 2019 /PRNewswire/ -- A new class of engineered proteins may counter infection caused by Staphylococcus aureus – a bacterial species considered one of the largest global health ...
As mentioned earlier, there is an urgent need for the development of novel antibiotics targeting S. aureus. Fortunately, a number of new agents active against MRSA and other Gram-positive pathogens ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results